Home Patent Forecast® Sectors Log In   Sign Up   Free Trial   Support   Contact   Pricing  
How it works Patent Forecast® Sectors Pricing Insights
Menu

GW Pharmaceutical creating CBDV medications for treating Autism, Schizophrenia

Z-ARCHIVE-Cannabis Patent Forecast®

June 20, 2019

A GW Pharmaceuticals cannabis patent application (2019/0160023) for the use of the cannabinoid cannabidivarin (CBDV) in the treatment of Autism, Schizophrenia, and related psychological disorders was published this month. Under GW Pharma’s Pharmaceutical Pipeline development, CBDV has entered into phase 2 of clinical trials. Once through phase 3, GW Pharma can submit an application to the FDA presenting their evidence to seek FDA approval of the purified CBDV drug, just as was done for their purified CBD drug Epidiolex.


Relevant Patent Documents

Application US20190160023  

Article Source Link

GW Pharmaceuticals


Z-ARCHIVE-Cannabis   Patent Forecast®

View Patent Forecast® Top Corporations News and Insights Data Visualization

For a blog.



301